Nexcella announced that updated NXC-201 clinical data has been selected to be presented at the upcoming European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting to be held in Rotterdam, Netherlands February 9-11, 2023. "We are delighted to be presenting additional clinical data at the upcoming at European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting," said Polina Stepensky, MD, Director of the Hadassah Medical Organization’s Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator. "As we continue to accumulate clinical data, we are learning more about the potential for this therapy to treat multiple myeloma and AL amyloidosis." Posters to be presented: "Point-of-care CART manufacture and delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center" Nexcella previously announced that NXC-201 produced 85% overall response rate and 71% complete response/stringent complete response at the therapeutic dose from the first 20 patients in an ongoing phase 1b/2a relapsed/refractory multiple myeloma ongoing clinical trial as of the June 27, 2022 data cutoff with a median of 6 prior lines of therapy. NXC-201 also produced 100% ORR and 100% organ response rate in 4 relapsed/refractory AL Amyloidosis patients as of the February 26, 2022 AL Amyloidosis manuscript publication date. In addition, zero neurotoxicity of any grade was observed and zero events of immune effector cell-associated neurotoxicity syndrome were observed with NXC-201 treatment. Low-grade CRS duration of median 2 days with median onset of 1-day post-dosing at therapeutic dose in relapsed/refractory multiple myeloma points to NXC-201 potentially becoming the first and only out-patient CAR-T for Multiple Myeloma, AL Amyloidosis and other BCMA-positive malignancies.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IMMX:
- Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting
- Immix announces 16th patient dosing in ongoing Phase 1b/2a IMX-110 trial
- Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
- ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors
- Immix Biopharma ships Tislelizumab for patient dosing in trial with IMX-110